LIFECORE BIOMEDICAL INC (LFCR)
US5147661046 - Common Stock
LFCR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 56 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of LFCR have multiple concerns. While showing a medium growth rate, LFCR is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year LFCR was profitable.
In the past year LFCR had a positive cash flow from operations.
LFCR had negative earnings in 4 of the past 5 years.
In the past 5 years LFCR reported 4 times negative operating cash flow.
1.2 Ratios
LFCR has a better Return On Assets (2.65%) than 76.79% of its industry peers.
The Return On Equity of LFCR (16.55%) is better than 89.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.65% | ||
| ROE | 16.55% | ||
| ROIC | N/A |
ROA(3y)-25.28%
ROA(5y)-17.88%
ROE(3y)-129.31%
ROE(5y)-84.12%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Profit Margin value of 5.09%, LFCR is doing good in the industry, outperforming 73.21% of the companies in the same industry.
LFCR's Profit Margin has improved in the last couple of years.
With a Gross Margin value of 34.65%, LFCR is not doing good in the industry: 64.29% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of LFCR has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 5.09% | ||
| GM | 34.65% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y164.95%
GM growth 3Y3.48%
GM growth 5Y17.57%
2. Health
2.1 Basic Checks
LFCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LFCR has more shares outstanding
LFCR has more shares outstanding than it did 5 years ago.
LFCR has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.34, we must say that LFCR is in the distress zone and has some risk of bankruptcy.
LFCR's Altman-Z score of 0.34 is on the low side compared to the rest of the industry. LFCR is outperformed by 69.64% of its industry peers.
A Debt/Equity ratio of 3.22 is on the high side and indicates that LFCR has dependencies on debt financing.
With a Debt to Equity ratio value of 3.22, LFCR is not doing good in the industry: 89.29% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.22 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.34 |
ROIC/WACCN/A
WACC9.81%
2.3 Liquidity
LFCR has a Current Ratio of 1.83. This is a normal value and indicates that LFCR is financially healthy and should not expect problems in meeting its short term obligations.
LFCR's Current ratio of 1.83 is on the low side compared to the rest of the industry. LFCR is outperformed by 66.07% of its industry peers.
LFCR has a Quick Ratio of 1.83. This is a bad value and indicates that LFCR is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.80, LFCR is doing worse than 89.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.83 | ||
| Quick Ratio | 0.8 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 101.64% over the past year.
Measured over the past years, LFCR shows a very strong growth in Earnings Per Share. The EPS has been growing by 100.00% on average per year.
The Revenue has grown by 52.11% in the past year. This is a very strong growth!
LFCR shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -25.47% yearly.
EPS 1Y (TTM)101.64%
EPS 3YN/A
EPS 5Y100%
EPS Q2Q%-50.29%
Revenue 1Y (TTM)52.11%
Revenue growth 3Y-9.23%
Revenue growth 5Y-25.47%
Sales Q2Q%0.75%
3.2 Future
Based on estimates for the next years, LFCR will show a very negative growth in Earnings Per Share. The EPS will decrease by -50.23% on average per year.
Based on estimates for the next years, LFCR will show a quite strong growth in Revenue. The Revenue will grow by 8.33% on average per year.
EPS Next Y-340.24%
EPS Next 2Y-93.49%
EPS Next 3Y-50.23%
EPS Next 5YN/A
Revenue Next Year2.51%
Revenue Next 2Y5.42%
Revenue Next 3Y7.4%
Revenue Next 5Y8.33%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 144.20, the valuation of LFCR can be described as expensive.
LFCR's Price/Earnings ratio is in line with the industry average.
When comparing the Price/Earnings ratio of LFCR to the average of the S&P500 Index (27.35), we can say LFCR is valued expensively.
The Forward Price/Earnings Ratio is negative for LFCR. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 144.2 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of LFCR is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 149.06 |
4.3 Compensation for Growth
LFCR's earnings are expected to decrease with -50.23% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)1.44
EPS Next 2Y-93.49%
EPS Next 3Y-50.23%
5. Dividend
5.1 Amount
No dividends for LFCR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LIFECORE BIOMEDICAL INC
NASDAQ:LFCR (12/30/2024, 11:19:36 AM)
7.21
-0.07 (-0.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners61.64%
Inst Owner ChangeN/A
Ins Owners1.53%
Ins Owner Change18.83%
Market Cap265.54M
Analysts77.78
Price Target8.16 (13.18%)
Short Float %6.72%
Short Ratio13.15
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.1%
Min EPS beat(2)-38.89%
Max EPS beat(2)-3.31%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)5.27%
Min Revenue beat(2)4.45%
Max Revenue beat(2)6.08%
Revenue beat(4)2
Avg Revenue beat(4)1.93%
Min Revenue beat(4)-2.14%
Max Revenue beat(4)6.08%
Revenue beat(8)3
Avg Revenue beat(8)-9.54%
Revenue beat(12)4
Avg Revenue beat(12)-14.44%
Revenue beat(16)4
Avg Revenue beat(16)-32.14%
PT rev (1m)14.29%
PT rev (3m)23.08%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-103.33%
EPS NY rev (1m)0%
EPS NY rev (3m)0.51%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-15.85%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 144.2 | ||
| Fwd PE | N/A | ||
| P/S | 2.07 | ||
| P/FCF | N/A | ||
| P/OCF | 35.55 | ||
| P/B | 6.72 | ||
| P/tB | 12.4 | ||
| EV/EBITDA | 149.06 |
EPS(TTM)0.05
EY0.69%
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)0.2
OCFY2.81%
SpS3.49
BVpS1.07
TBVpS0.58
PEG (NY)N/A
PEG (5Y)1.44
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.65% | ||
| ROE | 16.55% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 5.09% | ||
| GM | 34.65% | ||
| FCFM | N/A |
ROA(3y)-25.28%
ROA(5y)-17.88%
ROE(3y)-129.31%
ROE(5y)-84.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y164.95%
GM growth 3Y3.48%
GM growth 5Y17.57%
F-Score6
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.22 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 48.53 | ||
| Cap/Depr | 187.23% | ||
| Cap/Sales | 12.66% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 285.08% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.83 | ||
| Quick Ratio | 0.8 | ||
| Altman-Z | 0.34 |
F-Score6
WACC9.81%
ROIC/WACCN/A
Cap/Depr(3y)173.77%
Cap/Depr(5y)156.52%
Cap/Sales(3y)16.64%
Cap/Sales(5y)16.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)101.64%
EPS 3YN/A
EPS 5Y100%
EPS Q2Q%-50.29%
EPS Next Y-340.24%
EPS Next 2Y-93.49%
EPS Next 3Y-50.23%
EPS Next 5YN/A
Revenue 1Y (TTM)52.11%
Revenue growth 3Y-9.23%
Revenue growth 5Y-25.47%
Sales Q2Q%0.75%
Revenue Next Year2.51%
Revenue Next 2Y5.42%
Revenue Next 3Y7.4%
Revenue Next 5Y8.33%
EBIT growth 1Y72.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year278.26%
EBIT Next 3Y70.32%
EBIT Next 5YN/A
FCF growth 1Y82.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y127.91%
OCF growth 3YN/A
OCF growth 5YN/A